Dyslipidemia

An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.

Hyperuricemia was significantly linked to dyslipidemia and hypertriglyceridemia in hospitalized patients with type 2 diabetes, which remained after adjustment.

Variations in apoB concentration among Hispanic or Latino populations could provide important implications for apoB use in cardiovascular risk assessment.

Higher levels of small-particle HDL were linked with greater gray matter volume and higher cognitive capacity among middle-aged adults.

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.

Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.

A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.

Tirzepatide's approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.

A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.

CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.

Olezarsen ushers in a new era of care as the first therapy to receive FDA approval for adults with familial chylomicronemia syndrome as an adjunct to diet.

Submission of the Biologics License Application seeks approval of lerodalcibep to lower LDL-C in patients with or at risk for ASCVD and primary hyperlipidemia.

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

Muvalaplin, an oral treatment, reduced Lp(a) by up to 85% in a 12-week Phase 2 trial presented at AHA 2024.

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.

A 6-year longitudinal study, involving more than 200,000 adults, reported a notable rise in dyslipidemia incidence during the COVID-19 pandemic.

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

A new AHA statement highlights the benefits of lipoprotein apheresis for familial hypercholesterolemia and urges broader access to the underutilized therapy.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

Elucid has received 510(k) clearance for its PlaqueIQ™ imaging analysis software to help physicians diagnose cardiovascular disease.

Subclinical atherosclerosis burden and its progression are independently linked to the risk of death from any cause in asymptomatic individuals.

Family Heart Foundation announces the launch of Cholesterol Connect, a program that provides free at-home lipid screening and personalized support.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

Expert clinical consensus from the National Lipid Association finds ApoB testing is useful to stratify ASCVD risk more accurately than LDL-C.

The approval to GE Healthcare's cyclotron-produced radioactive diagnostic drug provides another option to adequately identify significant coronary artery disease.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

Elias discusses the challenges of prosthetic valve evaluation, highlighting the role of sonographers, Doppler imaging, and the importance of ongoing training.